Theravance Biopharma Approves Merger with Zymeworks

What Happened
Theravance Biopharma, Inc. announced that its shareholders approved the proposed merger with Zymeworks Inc. at an Extraordinary General Meeting held on September 18, 2026. The Merger Agreement (dated June 28, 2026) contemplates Merger Sub merging into Theravance Biopharma, with Theravance becoming a wholly owned subsidiary of Zymeworks and certain corporate charter changes and a Contingent Value Rights (CVR) arrangement. As of the July 31, 2026 record date there were 51,918,754 ordinary shares outstanding and 41,086,774 shares (79.14%) were represented at the meeting. The company expects the merger to close on or about September 23, 2026, subject to satisfaction or waiver of closing conditions.

Key Details

• Shareholder vote results for Proposal 1 (Merger): 40,993,370 For; 8,671 Against; 84,733 Abstentions — approved by more than two‑thirds (a closing condition under the Merger Agreement).
• Advisory vote on merger‑related executive compensation (Proposal 2): 40,587,829 For; 470,381 Against; 28,564 Abstentions — advisory approval obtained.
• Quorum/attendance: 41,086,774 shares voted (79.14% of outstanding). No broker non‑votes occurred because matters were non‑routine.
• Transaction mechanics include amendment/restatement of the company’s memorandum and articles, an authorized share capital change for the surviving Cayman entity, and a CVR agreement addressing contingent payments.

Why It Matters
Shareholder approval clears a key condition for the merger to proceed, bringing Theravance Biopharma under Zymeworks ownership if remaining closing conditions are met. Investors should note the CVR component (contingent payments tied to future drug development outcomes) and that timing and any contingent consideration remain uncertain. The vote also provided non‑binding approval of executive change‑in‑control payments; such approvals can affect post‑transaction costs and executive retention.